Newswise — Washington, DC—The Endocrine Society lauds Novo Nordisk’s recent announcement that it would limit price increases for its therapies, including insulin, and hopes that other entities in the insulin supply chain including manufacturers, pharmacy benefit managers, and insurers will also demonstrate similar restraint to address this important issue.
People with type 1 diabetes are unable to produce their own insulin and need insulin treatment to maintain their glucose control. People with the more common type 2 diabetes do not produce enough insulin and may need insulin treatment as well. Many people with diabetes depend on insulin, yet increasing prices creates a dangerous barrier to access this critical therapy.
The Society strongly advocates for people with diabetes who depend on insulin to treat their disease to have affordable access to this life-saving therapy. The Society will work with all stakeholders to determine both the cause of increasing prices as well as additional ways to ensure access to insulin.
The Society believes that with greater transparency across the insulin supply chain, stakeholders can work together to make drug pricing more predictable, reduce out-of-pocket costs, and help patients and providers have access to affordable, patient-centered therapies.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
RSS